Cargando…

Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis

Nonalcoholic fatty liver disease continues to be one of the major health challenges facing the world, with estimates of non-alcoholic steatohepatitis (NASH) prevalence in over 25 percent of the world’s population. NASH represents a spectrum of disease that may lead to hepatic fibrosis and eventual c...

Descripción completa

Detalles Bibliográficos
Autor principal: Kram, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011901/
https://www.ncbi.nlm.nih.gov/pubmed/36926236
http://dx.doi.org/10.4254/wjh.v15.i2.201
_version_ 1784906503080116224
author Kram, Michael
author_facet Kram, Michael
author_sort Kram, Michael
collection PubMed
description Nonalcoholic fatty liver disease continues to be one of the major health challenges facing the world, with estimates of non-alcoholic steatohepatitis (NASH) prevalence in over 25 percent of the world’s population. NASH represents a spectrum of disease that may lead to hepatic fibrosis and eventual cirrhosis, with the risk of cirrhosis decompensation, and hepatocellular carcinoma. New therapies are desperately needed for NASH, especially for later stages of fibrosis and cirrhosis. Galectin-3 inhibition is being explored as a new liver antifibrotic therapy. This concise review will outline the state of the art of this new therapeutic target.
format Online
Article
Text
id pubmed-10011901
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-100119012023-03-15 Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis Kram, Michael World J Hepatol Minireviews Nonalcoholic fatty liver disease continues to be one of the major health challenges facing the world, with estimates of non-alcoholic steatohepatitis (NASH) prevalence in over 25 percent of the world’s population. NASH represents a spectrum of disease that may lead to hepatic fibrosis and eventual cirrhosis, with the risk of cirrhosis decompensation, and hepatocellular carcinoma. New therapies are desperately needed for NASH, especially for later stages of fibrosis and cirrhosis. Galectin-3 inhibition is being explored as a new liver antifibrotic therapy. This concise review will outline the state of the art of this new therapeutic target. Baishideng Publishing Group Inc 2023-02-27 2023-02-27 /pmc/articles/PMC10011901/ /pubmed/36926236 http://dx.doi.org/10.4254/wjh.v15.i2.201 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Minireviews
Kram, Michael
Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis
title Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis
title_full Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis
title_fullStr Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis
title_full_unstemmed Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis
title_short Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis
title_sort galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011901/
https://www.ncbi.nlm.nih.gov/pubmed/36926236
http://dx.doi.org/10.4254/wjh.v15.i2.201
work_keys_str_mv AT krammichael galectin3inhibitionasapotentialtherapeutictargetinnonalcoholicsteatohepatitisliverfibrosis